Cerus Corporation (NASDAQ: CERS) today announced that the American Red
Cross will participate in Cerus’ clinical protocol to make the INTERCEPT
Blood System for platelets available under an Expanded Access
Investigational Device Exemption (IDE) to regions in the United States
with outbreaks of chikungunya and dengue virus.
for American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety Risks investment picks